Fred Alger Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-26,977
| Closed | -$1.58M | – | 507 |
|
|
2023
Q4 | $1.58M | Buy |
+26,977
| New | +$1.52M | 0.01% | 346 |
|
|
2022
Q1 | – | Sell |
-53,150
| Closed | -$7.8M | – | 564 |
|
|
2021
Q4 | $7.8M | Buy |
+53,150
| New | +$8.25M | 0.02% | 258 |
|
|
2021
Q3 | – | Sell |
-7,353
| Closed | -$1.19M | – | 578 |
|
|
2021
Q2 | $1.19M | Sell |
7,353
-314
| -4% | -$50.4K | ﹤0.01% | 381 |
|
|
2021
Q1 | $1.31M | Sell |
7,667
-8,596
| -53% | -$1.7M | ﹤0.01% | 365 |
|
|
2020
Q4 | $3.57M | Buy |
16,263
+4,890
| +43% | +$1.06M | 0.01% | 297 |
|
|
2020
Q3 | $1.89M | Buy |
11,373
+5,373
| +90% | +$735K | 0.01% | 305 |
|
|
2020
Q2 | $685K | Sell |
6,000
-3,000
| -33% | -$291K | ﹤0.01% | 378 |
|
|
2020
Q1 | $692K | Sell |
9,000
-3,500
| -28% | -$314K | ﹤0.01% | 342 |
|
|
2019
Q4 | $1.61M | Buy |
12,500
+500
| +4% | +$48.2K | 0.01% | 306 |
|
|
2019
Q3 | $935K | Buy |
12,000
+7,000
| +140% | +$657K | ﹤0.01% | 334 |
|
|
2019
Q2 | $515K | Sell |
5,000
-1,000
| -17% | -$77.9K | ﹤0.01% | 380 |
|
|
2019
Q1 | $440K | Buy |
+6,000
| New | +$408K | ﹤0.01% | 375 |
|
|
2018
Q4 | – | Sell |
-10,000
| Closed | -$471K | – | 584 |
|
|
2018
Q3 | $471K | Buy |
10,000
+2,000
| +25% | +$111K | ﹤0.01% | 360 |
|
|
2018
Q2 | $394K | Buy |
+8,000
| New | +$302K | ﹤0.01% | 363 |
|
Other funds holding MRTX
Fred Alger Management's MRTX Position: Q1 2024 in Review
Fred Alger Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 26,977 shares — an estimated $1.58M sold.
Fred Alger Management first reported a position in MRTX in Q2 2018 and held it in 14 quarters. The position peaked at $7.8M in Q4 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- Fred Alger Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Fred Alger Management sold 26,977 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.58M.
- Fred Alger Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 14 quarters.
- Fred Alger Management's Mirati Therapeutics, Inc. Common Stock position peaked at $7.8M in Q4 2021.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Fred Alger Management's 13F filing for Q1 2024, filed 15 May 2024.